Cytokinetics Newsroom

FDA Accepts Bayer's Application for Label Expansion of Nubeqa

Zacks Nov 22 13:00 ET

Cytokinetics Price Target Raised to $103 From $99 at Mizuho

Yahoo FinanceNov 22 06:51 ET

Why Is Cytokinetics, Incorporated (CYTK) Among the Worst Performing Biotech Stocks in 2024?

Yahoo FinanceNov 21 17:39 ET

Mizuho Maintains Outperform on Cytokinetics, Raises Price Target to $103

BenzingaNov 21 08:10 ET · Ratings

Express News | Cytokinetics Inc : Mizuho Raises Target Price to $103 From $99

ReutersNov 21 06:46 ET

Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan

Zacks Nov 21 02:29 ET

Unusual Options Activity: MET, CNH and Others Attract Market Bets, MET V/OI Ratio Reaches 318.2

Moomoo NewsNov 20 13:30 ET

A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $70 to $120

Moomoo NewsNov 20 08:00 ET · Ratings

Cytokinetics' Hold Rating Amid Bayer Partnership and Acquisition Uncertainty

TipRanksNov 20 06:16 ET · Ratings

Cytokinetics Gains 'Buy' Rating Due to Strategic Collaborations and Potential FDA Approval

TipRanksNov 19 16:05 ET · Ratings

Cytokinetics Partnership Demonstrates Value of Aficamten, Says JMP Securities

TipRanksNov 19 13:10 ET

Cytokinetics Secures Strategic Licensing Deal With Bayer, Boosting Global Prospects for Aficamten

TipRanksNov 19 12:55 ET

Cytokinetics, Bayer Partner to Develop, Commercialize Potential Cardiomyopathy Treatment in Japan

MT NewswiresNov 19 05:31 ET

Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan

Yahoo FinanceNov 19 05:26 ET

Bayer has reached a partnership with cytokinetics (CYTK.US) to develop and commercialize the hypertrophic cardiomyopathy treatment Aficamten in Japan.

Bayer has reached a collaboration agreement with cytokinetics to obtain the exclusive development and commercialization rights for Cytokinetics' hypertrophic cardiomyopathy (HCM) therapy, Aficamten, in japan, but must adhere to certain development rights retained by Cytokinetics.

Zhitong FinanceNov 19 03:54 ET

Express News | Cytokinetics Inc - Bayer to Conduct Phase 3 Trial in Japanese Patients With Obstructive HCM

ReutersNov 19 02:30 ET

Express News | Cytokinetics Inc - to Receive €50 Million Upfront, up to €90 Million in Milestones

ReutersNov 19 02:30 ET

Express News | Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan

ReutersNov 19 02:30 ET

Positive Clinical Outcomes Drive Buy Rating for Cytokinetics's Cardiac Myosin Modulators

TipRanksNov 18 06:16 ET · Ratings

Reported Saturday, Cytokinetics Shares Additional GALACTIC-HF Insights At AHA 2024

BenzingaNov 18 02:32 ET